1. Scrip
  2. >>Business
  3. >>Deals

Sanofi Stumps Up $125m To Access Denali RIPK1 Inhibitors

 
• By Kevin Grogan

The French drugmaker is dipping its toe into Alzheimer's disease as part of a CNS and inflammatory alliance with Denali which could net the US firm $1bn on top of a hefty upfront fee.

Brains
Sanofi and Denali put their brains together • Source: Shutterstock

Sanofi is taking the external route again to boost its early-stage pipeline by paying $125m upfront to Denali Therapeutics Inc. as part of a collaboration exploring neurological and inflammatory diseases.

The pact initially involves the development of two drugs that target receptor-interacting serine/threonine-protein kinase 1 (RIPK1), which regulates inflammation and cell death in tissues

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Pharma Left Hanging After US/UK Trade Pact

 
• By Kevin Grogan

An ‘historic economic prosperity deal’ does not include the sector.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from Business